Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody.
James Waldron
Apr 3, 2025 8:05am
Apollomics sells Asia rights to c-MET inhibitor in $60M deal
Mar 31, 2025 9:44am
Candel's cancer survival data light path ahead in subpopulation
Mar 27, 2025 9:48am
Servier pays $70M for Black Diamond's deprioritized cancer drug
Mar 19, 2025 7:53am
Kiromic furloughs 'substantially all' workers amid cash crunch
Mar 18, 2025 5:42am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
